Cargando…
Amlamax™ in the Management of Dyslipidemia in Humans
Hypercholesterolemia is the major cause of cardiovascular diseases leading to myocardial infarctions leading to considerable morbidity and mortality. During the past decade a group of molecules referred to as statins such as simvastatin, atrovastatin have been tried with great success in reducing to...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2792547/ https://www.ncbi.nlm.nih.gov/pubmed/20046781 http://dx.doi.org/10.4103/0250-474X.44604 |
_version_ | 1782175254974562304 |
---|---|
author | Antony, B. Merina, B. Sheeba, V. |
author_facet | Antony, B. Merina, B. Sheeba, V. |
author_sort | Antony, B. |
collection | PubMed |
description | Hypercholesterolemia is the major cause of cardiovascular diseases leading to myocardial infarctions leading to considerable morbidity and mortality. During the past decade a group of molecules referred to as statins such as simvastatin, atrovastatin have been tried with great success in reducing total cholesterol. These molecules act by inhibiting the HMG CoA reductase enzyme thereby interfering with the synthesis of cholesterol. But statins reduce all the cholesterol including HDL cholesterol. Long term drug vigilance activity has revealed serious side effects of tendinopathy and related musculoskeletal disorders in some of the subjects. In an effort to manage hypercholesterolemia without serious side effects in a natural way we had tried the use of Amlamax™ a reconstituted, purified, standardized dried extract of amla (Emblica officinalis) containing 30% ellagitannins with other hydrolysable tannins on humans. We report the hitherto unobserved significant elevation of HDL cholesterol by the administration of Amlamax™ |
format | Text |
id | pubmed-2792547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Medknow Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-27925472009-12-14 Amlamax™ in the Management of Dyslipidemia in Humans Antony, B. Merina, B. Sheeba, V. Indian J Pharm Sci Short Communications Hypercholesterolemia is the major cause of cardiovascular diseases leading to myocardial infarctions leading to considerable morbidity and mortality. During the past decade a group of molecules referred to as statins such as simvastatin, atrovastatin have been tried with great success in reducing total cholesterol. These molecules act by inhibiting the HMG CoA reductase enzyme thereby interfering with the synthesis of cholesterol. But statins reduce all the cholesterol including HDL cholesterol. Long term drug vigilance activity has revealed serious side effects of tendinopathy and related musculoskeletal disorders in some of the subjects. In an effort to manage hypercholesterolemia without serious side effects in a natural way we had tried the use of Amlamax™ a reconstituted, purified, standardized dried extract of amla (Emblica officinalis) containing 30% ellagitannins with other hydrolysable tannins on humans. We report the hitherto unobserved significant elevation of HDL cholesterol by the administration of Amlamax™ Medknow Publications 2008 /pmc/articles/PMC2792547/ /pubmed/20046781 http://dx.doi.org/10.4103/0250-474X.44604 Text en © Indian Journal of Pharmaceutical Sciences http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communications Antony, B. Merina, B. Sheeba, V. Amlamax™ in the Management of Dyslipidemia in Humans |
title | Amlamax™ in the Management of Dyslipidemia in Humans |
title_full | Amlamax™ in the Management of Dyslipidemia in Humans |
title_fullStr | Amlamax™ in the Management of Dyslipidemia in Humans |
title_full_unstemmed | Amlamax™ in the Management of Dyslipidemia in Humans |
title_short | Amlamax™ in the Management of Dyslipidemia in Humans |
title_sort | amlamax™ in the management of dyslipidemia in humans |
topic | Short Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2792547/ https://www.ncbi.nlm.nih.gov/pubmed/20046781 http://dx.doi.org/10.4103/0250-474X.44604 |
work_keys_str_mv | AT antonyb amlamaxinthemanagementofdyslipidemiainhumans AT merinab amlamaxinthemanagementofdyslipidemiainhumans AT sheebav amlamaxinthemanagementofdyslipidemiainhumans |